Roche & Zealand join forces on petrelintide, advancing obesity treatments with innovative amylin analogs. Find out why this deal is a win-win for RHHBY & ZLDPF.

AbbVie is joining the chase for new obesity drugs, but rather than getting a me-too GLP-1 drug, the pharmaceutical giant is landing rights to a clinical-stage molecule that goes after two novel ...

The licensing pact adds a second so-called "triple agonist" to the Danish drugmaker's portfolio as competition with Lilly and ...

With reference to AbbVie's (NYSE:ABBV) and Gubra A/S' (CPSE:GUBRA) joint announcement of March 3, 2025 regarding a license agreement to develop GUB014295, a potential best-in-class, ...

Novo Nordisk’s hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt ...

Lexicon's LX9851 targets ACSL5, a liver enzyme involved in fat metabolism that helps moderate fat accumulation and slow down ...

Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, ...

AbbVie ABBV announced that it has entered into a licensing agreement with Denmark-based biotech Gubra for the latter’s experimental obesity drug, GUB014295. This marks the American drugmaker’s ...

Roche Holding said it would pay Danish biotechnology research company Zealand Pharma up to $5.3 billion under an agreement to ...

MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is being studied in multiple Phase 2b clinical trials with read-outs ...

In addition, there will be a $350 million up-front payment as Abbvie takes over the reins of GUB-014295 (referred to as Gubamy), a long-acting analog of the satiety hormone amylin, currently in phase ...